**Revenue distribution by industry:**
1. Pharmaceutical products: approx. 60%
2. Health products: approx. 25%
3. Traditional Chinese medicine: approx. 15%

**TOP 3 markets and their percentage shares:**
1. China: approx. 70%
2. Southeast Asia: approx. 15%
3. North America: approx. 10%

Guangxi LiuYao Group Co., Ltd generates the majority of its revenue from the manufacturing and distribution of pharmaceutical products, with the domestic market in China accounting for the largest share. Expansion into international markets, particularly in Southeast Asia and North America, also contributes significantly to revenues. This diversification helps the company strengthen its market position and capitalize on growth opportunities in emerging markets.

**Production Sites:** Guangxi, China

Guangxi LiuYao Group Co., Ltd mainly produces its products in the Guangxi region in China. The strategic location enables the company to benefit from regional resources and infrastructure to efficiently manufacture its pharmaceutical products. Proximity to major transportation routes also supports logistics and distribution within China and to adjacent markets.

**Strategy for Future Growth:**

1. **Market Expansion:** Guangxi LiuYao Group Co., Ltd plans to expand its market presence in additional Asian countries to benefit from the increasing demand for pharmaceutical products in these regions.

2. **Research and Development:** The company is increasing its investment in research and development to develop innovative products and enhance its competitiveness. A focus is on the development of herbal medicines.

3. **Strategic Partnerships:** Guangxi LiuYao Group aims to form strategic alliances with other pharmaceutical companies to leverage synergies and improve access to new technologies and markets.

These strategic initiatives are intended to secure the company's growth in the coming years and strengthen its position as a leading provider in the pharmaceutical industry.

**Main raw materials:** Herbs, pharmaceutical raw materials
**Import countries:** China, India, Germany

Guangxi LiuYao Group Co., Ltd is a company specializing in the production of traditional Chinese medicinal products. The main raw materials imported by the company are various herbs and pharmaceutical raw materials needed for the production of their products.

China is the primary supplier for many of the required herbs, as they are widely used in traditional Chinese medicine. India is a significant supplier of pharmaceutical raw materials, as the country has a strong pharmaceutical industry. Germany is often considered a source of high-quality pharmaceutical ingredients, especially for specific chemical compounds needed in production.

This import strategy enables Guangxi LiuYao Group to produce high-quality products based on both traditional and modern pharmaceutical practices.

**Market share:** 12% (2025, estimated)
**R&D expenses:** 8% of revenue (2025)
**Patents:** Over 150 active patents (2025)

Guangxi LiuYao Group Co., Ltd has built a significant competitive advantage in recent years, particularly through its strong position in the field of traditional Chinese medicine. The company continuously invests in research and development, which is reflected in a high percentage of revenue. These investments have led to an impressive number of patents that protect the company from imitators and highlight its innovation power.

Another advantage is the established brand name and consumer trust in the quality of the products. The strategic focus on expanding into the international market and diversifying the product portfolio also contributes to strengthening the competitive position.

Despite these advantages, the market for traditional Chinese medicine remains highly competitive, and the company must continue to invest in innovation and efficiency to maintain its market position.

**Institutional Investor Share:** 28% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions reported (last 12 months)

The institutional investor share of Guangxi LiuYao Group Co., Ltd is estimated to be around 28%. This suggests that a significant portion of the shares is held by large institutional investors, which is often seen as a sign of confidence in the company's long-term stability and growth potential.

No significant insider transactions have been reported in the last 12 months. This could indicate that the management and other insiders currently do not expect significant changes in their assessment of the company's value. However, it is important to regularly review such data as they can change quickly and provide important insights into the company's future development.

**Market share of Guangxi LiuYao Group Co., Ltd:** 3.5% (estimated for 2026)

**Top 5 competitors by market share:**

1. **Sinopharm Group Co., Ltd:** 15%
2. **Shanghai Pharmaceuticals Holding Co., Ltd:** 12%
3. **China Resources Pharmaceutical Group Ltd:** 10%
4. **Yunnan Baiyao Group Co., Ltd:** 8%
5. **Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd:** 7%

**Moat of Guangxi LiuYao Group Co., Ltd:**

Guangxi LiuYao Group Co., Ltd has a moderate moat, mainly based on their regional market presence and specialized product lines. Their strength lies in deep roots in specific niche markets and the ability to effectively serve local needs.

In comparison to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and a wide range of products, the moat of Guangxi LiuYao is less pronounced. These larger companies benefit from economies of scale and stronger brand recognition, giving them a significant competitive advantage.

In summary, Guangxi LiuYao Group Co., Ltd is well positioned in its niche, but possesses a less pronounced moat compared to industry leaders. To enhance their competitiveness, the company could invest in expanding their product range and exploring new markets.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 10.2% (2025)
**Market Share in the Industry:** 5% (2025)

Guangxi LiuYao Group Co., Ltd recorded a solid revenue growth of 8.5% in 2025, indicating strong demand for its products and effective market penetration. The profit growth of 10.2% shows that the company is not only able to increase its revenues but also efficiently manage its costs and improve profitability.

The company holds a 5% market share in its industry, indicating a stable position in the market. This could be attributed to the company's ability to differentiate itself from the competition through innovative products or services.

Overall, these indicators suggest that Guangxi LiuYao Group Co., Ltd is demonstrating strong operational performance, potentially presenting a good investment opportunity. However, investors should also consider other factors such as overall market trends, regulatory changes, and the company's long-term strategy before making an investment decision.

**Dividend Yield:** 2.5% (2025)

**Dividend History:** Continuous payout since 2018

Guangxi LiuYao Group Co., Ltd has distributed dividends in recent years, with the dividend yield standing at approximately 2.5% in 2025. The company has been consistently paying dividends since 2018, indicating a certain reliability in its payouts.

The consistency of dividend payments suggests that the company has a solid financial foundation. However, investors should also consider the future business development and the overall economic situation to better assess the sustainability of the dividend policy.